Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: The EPICOR study

Licia Iacoviello, Claudia Agnoli, Amalia De Curtis, Augusto Di Castelnuovo, Maria Concetta Giurdanella, Vittorio Krogh, Amalia Mattiello, Giuseppe Matullo, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Giovanni De Gaetano, Salvatore Panico, Maria Benedetta Donati

Research output: Contribution to journalArticle

Abstract

Objectives: We examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke. Design: Nested case-cohort study. Setting: The European Prospective Investigation into Cancer and Nutrition-Italy cohort. Participants: A centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. Main outcomes and measures: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95% CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method. Results: Individuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28;95% CI 1.46 to 3.55; P for trend

Original languageEnglish
Article number12
JournalBMJ Open
Volume3
Issue number11
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: The EPICOR study'. Together they form a unique fingerprint.

  • Cite this